The Optimal Duration of Dual Antiplatelet Therapy After Implantation of Endeavor Stent

• Status: Completed
• Trial end date: 2009-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study to determine whether the dual antiplatelet therapy (aspirin and clopidogrel) for 3 months after coronary implantation of zotarolimus-eluting stent is safe in terms of death, myocardial infarction, or stent thrombosis.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Samsung Medical Center
• Collaborator: Medtronic
• Treatments: Aspirin; Clopidogrel

Criteria

Inclusion Criteria:

• Patients with clinically significant de novo coronary artery disease

• Stenting only with Endeavor® stents

• The sum of stent length is less than 60 mm for one lesion. The sum of stent length in multiple lesions does not matter.

Exclusion Criteria:

• Cardiogenic shock

• ST-elevation myocardial infarction within 48 hours of symptom onset

• Prior implantation of drug-eluting stents

• Left ventricular dysfunction (echocardiographic left ventricular ejection fraction < 25%)

• Stenting both branch of bifurcation lesion

• Left main trunk lesion

• Graft vessels

• Patients who have to receive clopidogrel due to other conditions

• Patients who have to receive warfarin, cilostazol or other antiplatelet therapy

• Patient with chronic renal failure (S-Cr > 2.0 mg/dl)

• Hypersensitivity to clopidogrel or aspirin

• Expectant survival less than 1 year

• Women who plan to become pregnant

• Patients with bleeding diathesis (coagulopathy, thrombocytopenia or platelet dysfunction, Gastrointestinal or genitourinary bleeding within the prior 3 months)

• Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period.